References
- Vamvakas E C, Taswell H F. Epidemiology of blond transfusions. Transfusion 1994; 31: 355
- Schreiber G B, et al. The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 344: 1615
- Workshop on Criteria for Safety and Efficacy Evaluation of Oxygen Therapeutics as Red Cell Substitutes. Natcher Building, National Institute of Health, Bethesda, MD. September 27–21, 1999., http://www.fda.gov./cber/minutes/oxygenO92799.doc
- ADS Knowledge Base. Intern. Epidemiology of HIV/MDS. June 1991
- McNamara E. Experts urges safer blood supply. Associated Press., New York. October 1, 1999, http://www.newsday.com/ap/mmphs1w.htm
- Walraven G, et al. The impact of BIV-1 infection on child health in Sub-Saharan Africa. Trop Med Int Health 1996; 1: 3
- Hess J R, et al : Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobins. J Appl Physiol 1993; 74: 1769
- Simoni J, et al. : Generation of free oxygen radicals and the toxicity of hemoglobin solutions. Biomat Artif Cells Art Org 1993; 18: 119
- Simoni J, et al. Biocompatibility of hemoglobin solutions: II The inflammatory reactions of human monocytes and mouse peritoneal macrophages. Artif Organs 1990; 14: 91
- Simoni J, et al. : Cytokines and PAP release from human monocytes and macrophages: effect of hemoglobin and contaminants. Artif Cells Blood Substit immobil Biotechnol 1994; 22: 525
- Smoni J, et al. : Expression of adhesion molecules and von Willebrand factor in human coronary artery endothelial cells incubated with differently modified hemoglobin solutions. Artif Cells Blood Substit immobil Biotechnol 1997; 25: 211
- Solan E P, et al. Diaspirin cress-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock. A randomized controlled efficacy trial. JAMA 1999; 282: 1157
- D'Agnillo F, Chang T MS. Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties. Nature Biotechnol 1999; 16: 667
- Doherty D E, et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nature Biotechnol 1999; 17: 672
- Simoni J, et al. An improved blood substitute: in vivo evaluation of its hemodynamic effects. ASMO J 1996; 42: M773
- Simoni J, et al. Modified hemoglobin solution with desired pharmacological properties, does not activate the transcription factor NF-kB in human vascular endothelial cells. Artif Cells Blood Substit immobil Biotechnol 1997; 25: 193
- Simoni J, et al. An improved blood substitute: in vivo evaluation of its renal effects. ASMO J 1997; 43: M714
- Simoni J, et al. Improved blood substitute: evaluation of its effects on human endothelial cells. ASMOJ 1991; 44: M356
- Feola M, et al. Clinical trial of a hemoglobin based blood substitute in patients with sickle cell anemia. Surg Gynecol Obstet 1992; 174: 379